← All trials
NCT05026801
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 8, 2021
- Primary completion
- Aug 26, 2021
- Completion date
- Aug 26, 2021
- First posted
- Aug 30, 2021
- Last posted
- Oct 28, 2021
- Enrollment
- —
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Iterum TherapeuticsLead sponsor
- Iterum TherapeuticsOverall official - principal investigator
- Waterbury HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.